Fractyl Health (GUTS) Common Equity (2023 - 2026)
Fractyl Health's (GUTS) quarterly Common Equity came in at $21.4 million in Q1 2026, up 235.33% YoY from $6.4 million in Q1 2025, and up 126.02% on a QoQ basis from $9.5 million in Q4 2025.
Fractyl Health (GUTS) Common Equity (2023 - 2026) Analysis & Trends
Fractyl Health (GUTS) has 4 years of Common Equity data on file, last reported at $21.4 million in Q1 2026.
- Quarterly Common Equity rose 235.33% year-over-year to $21.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $21.4 million (up 235.33% YoY) and the FY2025 annual result came in at $9.5 million, down 66.73% from the prior year.
- Common Equity climbed to $21.4 million in Q1 2026, from $9.5 million in the prior quarter.
- In the past five years, Common Equity ranged from a high of $84.2 million in Q1 2024 to a low of -$325.1 million in Q4 2023.
- A 4-year average of -$72.2 million and a median of $6.4 million in 2025 frame the typical range for Common Equity.
- Annual changes were most pronounced in 2025 — Common Equity slumped 125.74% — and 2026, when it surged 235.33%.
- Tracing GUTS's Common Equity over 4 years: stood at -$325.1 million in 2023, then soared by 108.74% to $28.4 million in 2024, then plunged by 66.73% to $9.5 million in 2025, then soared by 126.02% to $21.4 million in 2026.
- The last three Common Equity figures came in at $21.4 million (Q1 2026), $9.5 million (Q4 2025), and -$3.2 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 6.76 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 5.17 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.35 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 757.49 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 9.79 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 22.38 Bn |
| 10 | Fractyl Health | 109.12 Mn | 109.12 Mn | - | -1.67 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -1.67 Mn |
| Mar 31, 2026 | 21.38 Mn |
| Dec 31, 2025 | 9.46 Mn |
| Sep 30, 2025 | -3.18 Mn |
| Jun 30, 2025 | -18.21 Mn |
| Mar 31, 2025 | 6.38 Mn |
| Dec 31, 2024 | 28.42 Mn |
| Sep 30, 2024 | 50.32 Mn |
| Jun 30, 2024 | 70.76 Mn |
| Mar 31, 2024 | 84.18 Mn |
| Dec 31, 2023 | -325.06 Mn |
| Sep 30, 2023 | -307.18 Mn |
| Jun 30, 2023 | -292.52 Mn |
| Mar 31, 2023 | -263.39 Mn |